Address
306 Carmody Road
Building 80
Institute for Molecular Bioscience
St Lucia, QLD
4072, Australia
Contact
Mark Blaskovich+61414955380
m.blaskovich@uq.edu.au
Website
Community for Open Antimicrobial Drug Discovery
CO-ADD is an open-access crowd sourcing initiative created to help researchers uncover new antibiotics, by providing free, unencumbered testing for activity against pathogenic bacteria and fungi/yeast. CO-AD includes SPARK, a community knowledge base.
CO-ADD and SPARK, the Shared Platform for Antibiotic Research and Knowledge, provide a platform to share expertise, results, & predictive models.
Technology:
Microorganisms:
Application:
Development stage:
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Infection prevention
- Antimicrobial stewardship
Microorganisms:
- Bacteria
- Fungi
- Yeasts
- Parasites
- Viruses
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Academia
- Company
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- CARB-X
- OTHER / NA
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- SSTI
- IAI
- SSI
- GII
- CNSI
Geographic origin:
- Oceania
- North America
- South America
- Eurasia
- Africa
N.A.
The Centre for Superbug Solutions is focused on therapeutic and diagnostic solutions to AMR. Based within IMB at UQ, it includes CO-ADD & SPARK.
1) OPX & OPX-P: lipopeptides for XDR G-ve strains, CARB-X funded. 2) Vancapticin: preclinical lipoglycopeptide. 3) Bicyclic nitroimidazole: MTb+parasites. 4) Toolset of antibiotic-derived fluoro probes. 5) Bacterial capture magnetic nanoparticles.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!